HC Wainwright reissued their buy rating on shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in a report published on Monday morning, Marketbeat Ratings reports. They currently have a $68.00 price objective on the medical instruments supplier’s stock, down from their prior price objective of $74.00.

XRAY has been the topic of several other research reports. Credit Suisse Group reaffirmed an outperform rating and issued a $75.00 target price (up previously from $67.00) on shares of DENTSPLY SIRONA in a report on Thursday, July 13th. BidaskClub lowered shares of DENTSPLY SIRONA from a hold rating to a sell rating in a report on Friday, July 28th. Zacks Investment Research raised shares of DENTSPLY SIRONA from a sell rating to a hold rating and set a $71.00 target price on the stock in a report on Tuesday, May 2nd. Stifel Nicolaus reaffirmed a buy rating and issued a $66.00 target price (down previously from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Finally, UBS AG reaffirmed a neutral rating and issued a $59.00 target price (down previously from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $66.25.

DENTSPLY SIRONA (XRAY) opened at 53.17 on Monday. DENTSPLY SIRONA has a 12-month low of $52.73 and a 12-month high of $65.68. The firm’s market capitalization is $12.20 billion. The stock has a 50 day moving average of $61.68 and a 200 day moving average of $62.21.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The firm had revenue of $992.70 million for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm posted $0.76 EPS. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. Equities research analysts anticipate that DENTSPLY SIRONA will post $2.72 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/18/dentsply-sirona-inc-xray-given-buy-rating-at-hc-wainwright.html.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 29th will be issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Thursday, September 28th. DENTSPLY SIRONA’s dividend payout ratio is currently -10.09%.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in DENTSPLY SIRONA by 3,103.7% in the first quarter. BlackRock Inc. now owns 13,891,329 shares of the medical instruments supplier’s stock worth $867,376,000 after buying an additional 13,457,730 shares during the last quarter. Principal Financial Group Inc. increased its position in DENTSPLY SIRONA by 1,445.2% in the first quarter. Principal Financial Group Inc. now owns 5,292,885 shares of the medical instruments supplier’s stock worth $330,488,000 after buying an additional 4,950,337 shares during the last quarter. Clearbridge Investments LLC increased its position in DENTSPLY SIRONA by 34.6% in the first quarter. Clearbridge Investments LLC now owns 5,258,060 shares of the medical instruments supplier’s stock worth $328,313,000 after buying an additional 1,353,040 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in DENTSPLY SIRONA during the first quarter worth about $64,184,000. Finally, Renaissance Technologies LLC increased its position in DENTSPLY SIRONA by 246.0% in the first quarter. Renaissance Technologies LLC now owns 1,044,558 shares of the medical instruments supplier’s stock worth $65,222,000 after buying an additional 742,700 shares during the last quarter. Institutional investors own 95.13% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Stock Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related stocks with our FREE daily email newsletter.